Compare Stocks: CMPX, AAPG, ANAB, and FBRX

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
AAPG Ascentage Pharma Group International	$17.61 +1.4%	$18.24	$16.23 ▼ $41.40	$1.65B	0.08	6,677 shs	5,078 shs
ANAB AnaptysBio	$56.80 -1.1%	$58.18	$11.40 ▼ $72.36	$1.68B	0.71	388,542 shs	1.06 million shs
CMPX Compass Therapeutics	$2.38 +0.4%	$2.22	$1.61 ▼ $6.88	$428.61M	0.95	2.84 million shs	2.54 million shs
FBRX Forte Biosciences	$76.99	$60.99	$10.11 ▼ $77.20	$1.63B	2.62	1.86 million shs	N/A

10 Best Stocks to Own - Summer 2026

Enter your email address and we’ll send you MarketBeat’s list of ten stocks set to soar in Summer 2026, despite the threat of tariffs and what's happening in Iran. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
AAPG Ascentage Pharma Group International	0.00%	-3.67%	+3.04%	+0.75%	-57.37%
ANAB AnaptysBio	0.00%	+0.92%	+3.71%	+12.77%	+152.11%
CMPX Compass Therapeutics	0.00%	-0.83%	+19.60%	+16.67%	-29.38%
FBRX Forte Biosciences	0.00%	0.00%	+0.21%	+366.04%	+595.48%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
AAPG Ascentage Pharma Group International	$17.61 +1.4%	$18.24	$16.23 ▼ $41.40	$1.65B	0.08	6,677 shs	5,078 shs
ANAB AnaptysBio	$56.80 -1.1%	$58.18	$11.40 ▼ $72.36	$1.68B	0.71	388,542 shs	1.06 million shs
CMPX Compass Therapeutics	$2.38 +0.4%	$2.22	$1.61 ▼ $6.88	$428.61M	0.95	2.84 million shs	2.54 million shs
FBRX Forte Biosciences	$76.99	$60.99	$10.11 ▼ $77.20	$1.63B	2.62	1.86 million shs	N/A

10 Best Stocks to Own - Summer 2026

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
AAPG Ascentage Pharma Group International	0.00%	-3.67%	+3.04%	+0.75%	-57.37%
ANAB AnaptysBio	0.00%	+0.92%	+3.71%	+12.77%	+152.11%
CMPX Compass Therapeutics	0.00%	-0.83%	+19.60%	+16.67%	-29.38%
FBRX Forte Biosciences	0.00%	0.00%	+0.21%	+366.04%	+595.48%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
AAPG Ascentage Pharma Group International	3.20	Buy	$46.43	163.65% Upside
ANAB AnaptysBio	2.67	Moderate Buy	$79.85	40.57% Upside
CMPX Compass Therapeutics	2.88	Moderate Buy	$11.77	394.51% Upside
FBRX Forte Biosciences	2.00	Hold	$71.67	-6.91% Downside

Current Analyst Ratings Breakdown

Latest CMPX, AAPG, ANAB, and FBRX Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/31/2026	ANAB AnaptysBio	Wolfe Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Outperform	$78.00
8/25/2026	ANAB AnaptysBio	TD Cowen Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Lower Price Target	Buy	$75.00 ➝ $70.00
8/25/2026	ANAB AnaptysBio	Scotiabank Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Hold	$70.00
8/24/2026	ANAB AnaptysBio	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy	$95.00
8/21/2026	AAPG Ascentage Pharma Group International	BTIG Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy	$48.00
8/14/2026	FBRX Forte Biosciences	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (E+) ➝ Sell (D-)
8/7/2026	ANAB AnaptysBio	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (E+)
8/7/2026	CMPX Compass Therapeutics	Piper Sandler Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Overweight	$4.00 ➝ $6.00
7/28/2026	FBRX Forte Biosciences	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Sell (D-) ➝ Sell (E+)
7/28/2026	FBRX Forte Biosciences	Barclays Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Overweight ➝ Equal Weight	$74.00 ➝ $77.00
7/27/2026	FBRX Forte Biosciences	Evercore Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Set Price Target		$77.00

(Data available from 9/5/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
AAPG Ascentage Pharma Group International	$82.10M	20.03	N/A	N/A	$0.89 per share	19.79
ANAB AnaptysBio	$234.60M	7.17	N/A	N/A	$1.34 per share	42.39
CMPX Compass Therapeutics	$850K	504.25	N/A	N/A	$0.92 per share	2.59
FBRX Forte Biosciences	N/A	N/A	N/A	N/A	$8.66 per share	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
AAPG Ascentage Pharma Group International	-$177.71M	N/A	N/A	880.50	N/A	N/A	N/A	N/A	N/A
ANAB AnaptysBio	-$13.23M	-$1.08	N/A	19.12	N/A	-11.53%	N/A	-7.75%	9/9/2026 (Estimated)
CMPX Compass Therapeutics	-$66.49M	-$0.40	N/A	N/A	N/A	N/A	-38.71%	-34.72%	11/4/2026 (Estimated)
FBRX Forte Biosciences	-$69.38M	-$4.65	N/A	N/A	N/A	N/A	-94.82%	-77.68%	11/13/2026 (Estimated)

Latest CMPX, AAPG, ANAB, and FBRX Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
9/9/2026	Q2 2026	ANAB AnaptysBio	-$0.4133	N/A	N/A	N/A	$6.67 million	N/A
8/19/2026	H1 2026	AAPG Ascentage Pharma Group International	N/A	-$0.65	N/A	-$0.6450	N/A	$22.24 million
8/12/2026	Q2 2026	FBRX Forte Biosciences	-$0.9950	-$0.97	+$0.0250	-$0.97	N/A	N/A
8/6/2026	Q2 2026	CMPX Compass Therapeutics	-$0.1107	-$0.13	-$0.0193	-$0.13	($0.60) million	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
AAPG Ascentage Pharma Group International	N/A	N/A	N/A	N/A	N/A
ANAB AnaptysBio	N/A	N/A	N/A	N/A	N/A
CMPX Compass Therapeutics	N/A	N/A	N/A	N/A	N/A
FBRX Forte Biosciences	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
AAPG Ascentage Pharma Group International	1.09	1.22	1.18
ANAB AnaptysBio	N/A	7.58	7.58
CMPX Compass Therapeutics	N/A	11.22	11.22
FBRX Forte Biosciences	N/A	10.01	10.01

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
AAPG Ascentage Pharma Group International	N/A
ANAB AnaptysBio	N/A
CMPX Compass Therapeutics	68.43%
FBRX Forte Biosciences	77.63%

Insider Ownership

Company	Insider Ownership
AAPG Ascentage Pharma Group International	N/A
ANAB AnaptysBio	31.50%
CMPX Compass Therapeutics	18.70%
FBRX Forte Biosciences	4.40%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
AAPG Ascentage Pharma Group International	600	93.40 million	N/A	N/A
ANAB AnaptysBio	100	29.61 million	20.28 million	Optionable
CMPX Compass Therapeutics	20	180.09 million	146.41 million	Not Optionable
FBRX Forte Biosciences	5	21.23 million	20.30 million	Optionable

CMPX, AAPG, ANAB, and FBRX Headlines

Recent News About These Companies

Forte Biosciences stock edges higher after argenx takeover closes

September 1, 2026 | ad-hoc-news.deA

Forte Biosciences Completed Take-Private Merger and Delisting

August 29, 2026 | theglobeandmail.com

Forte Biosciences (NASDAQ:FBRX) Rating Increased to Sell at Wall Street Zen

August 29, 2026 | americanbankingnews.com

Wall Street Zen Upgrades Forte Biosciences (NASDAQ:FBRX) to Sell

August 29, 2026 | marketbeat.com

Argenx Completes Acquisition of Forte Biosciences

August 27, 2026 | finance.yahoo.com

222,500 Shares in Forte Biosciences, Inc. $FBRX Purchased by AWM Investment Company Inc.

August 26, 2026 | marketbeat.com

Forte Biosciences (NASDAQ:FBRX) Sees Large Volume Increase - Here's What Happened

August 25, 2026 | marketbeat.com

Forte Biosciences (NASDAQ:FBRX) Sets New 1-Year High - What's Next?

August 20, 2026 | marketbeat.com

Forte Biosciences (NASDAQ:FBRX) Sees Strong Trading Volume - What's Next?

August 19, 2026 | marketbeat.com

Forte Biosciences, Inc. (NASDAQ:FBRX) Given Average Recommendation of "Hold" by Brokerages

August 15, 2026 | marketbeat.com

Forte Biosciences (NASDAQ:FBRX) Releases Earnings Results, Misses Estimates By $0.09 EPS

August 12, 2026 | marketbeat.com

Hedge Funds Favor argenx (ARGX) Over Forte Biosciences, Inc. (FBRX): Argenx Agrees to Buy Forte Biosciences

August 11, 2026 | insidermonkey.com

Forte Biosciences Investor Alert: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Forte Biosciences, Inc. - FBRX

August 11, 2026 | businesswire.com

FBRX Stock Alert: Halper Sadeh LLC is Investigating Whether Forte Biosciences, Inc. is Obtaining a Fair Price for its Shareholders

August 8, 2026 | businesswire.com

The M&A Class Action Firm Encourages $hareholders To Contact Monteverde Concerning The Merger—FBRX, LXFR, SMTI, and MKTX

August 6, 2026 | globenewswire.com

argenx Announces Commencement of Tender Offer to Acquire Forte Biosciences, Inc.

August 6, 2026 | globenewswire.com

$HAREHOLDER ALERT: The M&A Class Action Firm Continues To Investigate The Merger—FBRX, LXFR, SMTI, and MKTX

August 4, 2026 | globenewswire.com

Forte Biosciences (FBRX) Agrees To argenx Takeover As Tender Offer Nears

July 29, 2026 | finance.yahoo.com

Halper Sadeh LLC is Investigating Whether FBRX and SAFT are Obtaining Fair Deals for their Shareholders

July 28, 2026 | globenewswire.com

Forte Biosciences Investor Alert: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Forte Biosciences, Inc. - FBRX

July 28, 2026 | businesswire.com

argenx boosts immuno expertise with buy of Forte Biosciences

July 28, 2026 | thepharmaletter.comT

New MarketBeat Followers Over Time

Media Sentiment Over Time

CMPX, AAPG, ANAB, and FBRX Company Descriptions

Ascentage Pharma Group International NASDAQ:AAPG

$17.61 +0.25 (+1.44%)

As of 09/4/2026 03:59 PM Eastern

Ascentage Pharma Group International Co., Ltd. is a clinical-stage biotechnology company. It engages in the development of novel therapies for cancers, hepatitis B virus, or HBV, and age-related diseases. The company was founded by Da Jun Yang, Wang Shao Meng and Ming Guo in May 2009 and is headquartered in Suzhou, China.

AnaptysBio NASDAQ:ANAB

$56.80 -0.66 (-1.15%)

As of 09/4/2026 04:00 PM Eastern

AnaptysBio, Inc., a clinical-stage biotechnology company, focuses in delivering immunology therapeutics. Its products include Rosnilimab, an IgG1 antibody that targets PD-1+ T cells, resulting in their agonism or depletion, broadly impacting pathogenic drivers of autoimmune and inflammatory diseases; and ANB032, a non-depleting antibody that binds to the BTLA checkpoint receptor and inhibits activated T cell proliferation; ANB033, a novel anti-CD122 antagonist antibody that targets the shared common beta subunit of the receptors for IL-15 and IL-2; ANB101, a BDCA2 modulator antibody that specifically targets plasmacytoid dendritic cells (pDCs); and Imsidolimab, an antibody that inhibits the interleukin-36 receptor, which is in the Phase 3 development for the treatment of generalized pustular psoriasis. The company also focuses on developing various antibody programs that are advanced to preclinical and clinical milestones under its collaborations. It has a collaboration and license agreement with GlaxoSmithKline, Inc. The company was formerly known as Anaptys Biosciences, Inc. and changed its name to AnaptysBio, Inc. in July 2006. AnaptysBio, Inc. was incorporated in 2005 and is based in San Diego, California.

Compass Therapeutics NASDAQ:CMPX

$2.38 +0.01 (+0.42%)

As of 09/4/2026 04:00 PM Eastern

Compass Therapeutics, Inc., a clinical-stage oncology-focused biopharmaceutical company, engages in developing antibody-based therapeutics to treat various human diseases in the United States. The company's lead product candidates include CTX-009, a bispecific antibody that blocks Delta-like ligand 4 a ligand of Notch-1, and vascular endothelial growth factor A signaling pathways, which are critical to angiogenesis and tumor vascularization; and CTX-471, an IgG4 monoclonal antibody that is an agonist of CD137, a key co-stimulatory receptor on immune cells. It also develops CTX-8371, a bispecific inhibitor that targets PD-1 and PD-L1 checkpoint inhibitor antibodies. The company was founded in 2014 and is headquartered in Boston, Massachusetts.

Forte Biosciences NASDAQ:FBRX

$76.99 0.00 (0.00%)

As of 08/27/2026

Forte Biosciences, Inc. operates as a biopharmaceutical company in the United States. The company is developing FB-102 program that addresses various autoimmune diseases, such as graft-versus-host disease, and vitiligo and alopecia areata. Forte Biosciences, Inc. is headquartered in Dallas, Texas.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest CMPX, AAPG, ANAB, and FBRX Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest CMPX, AAPG, ANAB, and FBRX Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

CMPX, AAPG, ANAB, and FBRX Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

CMPX, AAPG, ANAB, and FBRX Company Descriptions

Ascentage Pharma Group International NASDAQ:AAPG

AnaptysBio NASDAQ:ANAB

Compass Therapeutics NASDAQ:CMPX

Forte Biosciences NASDAQ:FBRX

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest CMPX, AAPG, ANAB, and FBRX Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest CMPX, AAPG, ANAB, and FBRX Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

CMPX, AAPG, ANAB, and FBRX Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

CMPX, AAPG, ANAB, and FBRX Company Descriptions

Ascentage Pharma Group International NASDAQ:AAPG

AnaptysBio NASDAQ:ANAB

Compass Therapeutics NASDAQ:CMPX

Forte Biosciences NASDAQ:FBRX

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools